The current economic burden of cirrhosis

Gastroenterology and Hepatology

Volumn 7, Issue 10, 2011, Pages 661-671

  Neff, Guy W ^a   Duncan, Christopher W ^b   Schiff, Eugene R ^c  

^a Tampa General Medical Group   (United States)

^b Highline Gastroenterology   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Cirrhosis; Cost; Economic burden; Hepatitis B virus; Hepatitis C virus; Quality adjusted life years

Indexed keywords

ADEFOVIR; ALPHA2B INTERFERON; ENTECAVIR; LAMIVUDINE; PEGINTERFERON ALPHA2A; TELBIVUDINE; TENOFOVIR;

ALCOHOL CONSUMPTION; ALCOHOL LIVER DISEASE; COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; HEPATITIS B; HUMAN; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; QUALITY OF LIFE; REVIEW;

EID: 81155131675     PISSN: 15547914     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (110)

1. Heidelbaugh JJ, Bruderly M. Cirrhosis and chronic liver failure: part I. Diagnosis and evaluation. Am Fam Physician. 2006;74:756-762.
2. Salomon JA, Weinstein MC, Hammitt JK, Goldie SJ. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA. 2003;290:228-237. (Pubitemid 37430062)
3. Miniño AM, Xu J, Kochanek KD, Tejada-Vera B. Death in the United States, 2007. NCHS Data Brief. 2009;1-8.
4. Agency for Healthcare Research and Quality. HCUPnet. http://hcupnet.ahrq. gov.
5. Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology. 2010;138:513-521.
6. Ruhl CE, Sayer B, Byrd-Holt DE, Brown DM. Costs of digestive diseases. In: Everhart J, ed. The Burden of Digestive Diseases in the United States. Washington, DC: US Dept of Health and Human Services, Public Health Service, National Institutes of Health, and National Institute of Diabetes and Digestive and Kidney Diseases; 2008:137-143. NIH publication 09-6443.
7. Mast EE, Margolis HS, Fiore AE, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents. MMWR Recomm Rep. 2005;54(RR-16):1-31.
8. Mast EE, Weinbaum CM, Fiore AE, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part II: immunization of adults. MMWR Recomm Rep. 2006;55(RR-16):1-33.
9. Ni YH, Huang LM, Chang MH, et al. Two decades of universal hepatitis B vaccination in Taiwan: impact and implication for future strategies. Gastroenterology. 2007;132:1287-1293.
10. Alfaleh F, Alshehri S, Alansari S, et al. Long-term protection of hepatitis B vaccine 18 years after vaccination. J Infect. 2008;57:404-409.
11. Bialek SR, Bower WA, Novak R, et al. Persistence of protection against hepatitis B virus infection among adolescents vaccinated with recombinant hepatitis B vaccine beginning at birth: a 15-year follow-up study. Pediatr Infect Dis J. 2008;27:881-885.
12. But DY, Lai CL, Lim WL, Fung J, Wong DK, Yuen MF. Twenty-two years follow-up of a prospective randomized trial of hepatitis B vaccines without booster dose in children: final report. Vaccine. 2008;26:6587-6591.
13. McMahon BJ, Dentinger CM, Bruden D, et al. Antibody levels and protection after hepatitis B vaccine: results of a 22-year follow-up study and response to a booster dose. J Infect Dis. 2009;200:1390-1396.
14. Poorolajal J, Mahmoodi M, Majdzadeh R, Nasseri-Moghaddam S, Haghdoost A, Fotouhi A. Long-term protection provided by hepatitis B vaccine and need for booster dose: a meta-analysis. Vaccine. 2010;28:623-631.
15. Ramezani A, Eslamifar A, Banifazl M, et al. Efficacy and long-term immunogenicity of hepatitis B vaccine in haemodialysis patients. Int J Clin Pract. 2009;63:394-397.
16. Bloom BS, Hillman AL, Fendrick AM, Schwartz JS. A reappraisal of hepatitis B virus vaccination strategies using cost-effectiveness analysis. Ann Intern Med. 1993;118:298-306. (Pubitemid 23046389)
17. Hung HF, Chen TH. Probabilistic cost-effectiveness analysis of the long-term effect of universal hepatitis B vaccination: an experience from Taiwan with high hepatitis B virus infection and hepatitis B e antigen positive prevalence. Vaccine. 2009;27:6770-6776.
18. Kim SY, Salomon JA, Goldie SJ. Economic evaluation of hepatitis B vaccination in low-income countries: using cost-effectiveness affordability curves. Bull World Health Organ. 2007;85:833-842. (Pubitemid 350086455)
19. Krahn M, Guasparini R, Sherman M, Detsky AS. Costs and cost-effectiveness of a universal, school-based hepatitis B vaccination program. Am J Public Health. 1998;88:1638-1644. (Pubitemid 28499143)
20. Margolis HS, Coleman PJ, Brown RE, Mast EE, Sheingold SH, Arevalo JA. Prevention of hepatitis B virus transmission by immunization: an economic analysis of current recommendations. JAMA. 1995;274:1201-1208.
21. Tilson L, Thornton L, O'Flanagan D, Johnson H, Barry M. Cost-effectiveness of hepatitis B vaccination strategies in Ireland: an economic evaluation. Eur J Public Health. 2008;18:275-282. (Pubitemid 351786636)
22. Edmunds WJ. Universal or selective immunisation against hepatitis B virus in the United Kingdom? A review of recent cost-effectiveness studies. Commun Dis Public Health. 1998;1:221-228.
23. Rots NY, Wijmenga-Monsuur AJ, Luytjes W, et al. Hepatitis B vaccination strategies tailored to different endemicity levels: some considerations. Vaccine. 2010;28:893-900.
24. Hammitt LL, Hennessy TW, Fiore AE, et al. Hepatitis B immunity in children vaccinated with recombinant hepatitis B vaccine beginning at birth: a follow-up study at 15 years. Vaccine. 2007;25:6958-6964. (Pubitemid 47391099)
25. Williams JL, Christensen CJ, McMahon BJ, et al. Evaluation of the response to a booster dose of hepatitis B vaccine in previously immunized healthcare workers. Vaccine. 2001;19:4081-4085. (Pubitemid 32566334)
26. Loomba R, Liang TJ. Treatment of chronic hepatitis B. Antivir Ther. 2007;12(suppl 3):H33-H41.
27. Paat G, Uusküla A, Tefanova V, Tallo T, Priimägi L, Ahi K. The trends and risk factors for hepatitis B occurrence in Estonia. Cent Eur J Public Health. 2009;17:108-111.
28. Roush SW, Murphy TV; Vaccine-Preventable Disease Table Working Group. Historical comparisons of morbidity and mortality for vaccine-preventable diseases in the United States. JAMA. 2007;298:2155-2163. (Pubitemid 350106654)
29. Van Herck K, Vorsters A, Van Damme P. Prevention of viral hepatitis (B and C) reassessed. Best Pract Res Clin Gastroenterol. 2008;22:1009-1029.
30. Schmunis GA, Rodriguez G, Coenen J, Bellorin EG, Gianella A. Prevention of blood-borne diseases in Bolivia, 1993-2002. Am J Trop Med Hyg. 2008;79:803-808.
31. NIH consensus statement on management of hepatitis C: 2002. NIH Consens State Sci Statements. 2002;19:1-46.
32. Edlin BR, Kresina TF, Raymond DB, et al. Overcoming barriers to prevention, care, and treatment of hepatitis C in illicit drug users. Clin Infect Dis. 2005;40(suppl 5):S276-S285. (Pubitemid 40490212)
33. McHutchison JG, Bacon BR, Owens GS. Making it happen: managed care considerations in vanquishing hepatitis C. Am J Manag Care. 2007;13(suppl 12):S327-S336.
34. Mann RE, Smart RG, Rush BR, Zalcman RF, Suurvali H. Cirrhosis mortality in Ontario: effects of alcohol consumption and Alcoholics Anonymous participation. Addiction. 2005;100:1669-1679. (Pubitemid 41626827)
35. Ramstedt M. Population drinking and liver cirrhosis mortality: is there a link in Eastern Europe? Addiction. 2007;102:1212-1223. (Pubitemid 47037927)
36. Smart RG, Mann RE, Suurvali H. Changes in liver cirrhosis death rates in different countries in relation to per capita alcohol consumption and Alcoholics Anonymous membership. J Stud Alcohol. 1998;59:245-249. (Pubitemid 28194506)
37. Norström T, Ramstedt M. Mortality and population drinking: a review of the literature. Drug Alcohol Rev. 2005;24:537-547. (Pubitemid 43000460)
38. Anderson P, Chisholm D, Fuhr DC. Effectiveness and cost-effectiveness of policies and programmes to reduce the harm caused by alcohol. Lancet. 2009;373:2234-2246.
39. Toomey TL, Wagenaar AC. Policy options for prevention: the case of alcohol. J Public Health Policy. 1999;20:192-213. (Pubitemid 29318787)
40. Ferri M, Amato L, Davoli M. Alcoholics Anonymous and other 12-step programmes for alcohol dependence. Cochrane Database Syst Rev. 2006;3:CD005032.
41. Smart RG, Mann RE, Lee SL. Does increased spending on alcoholism treatment lead to lower cirrhosis death rates? Alcohol Alcohol. 1996;31:487-491. (Pubitemid 26388512)
42. Department of Vaccines and Biologicals, World Health Organization. Introduction of hepatitis B vaccine into childhood immunization services: management guidelines, including information for health workers and parents. http://whqlib-doc.who.int/hq/2001/WHO-V&B-01.31.pdf.
43. Department of Communicable Diseases Surveillance and Response, World Health Organization. Hepatitis B. http://www.who.int/cst/disease/hepatitis/ HepatitisB-whocdscsrlyo2002-2.pdf.
44. Hsieh CR, Kuo CW. Cost of chronic hepatitis B virus infection in Taiwan. J Clin Gastroenterol. 2004;38(10 suppl 3):S148-S152.
45. Lee TA, Veenstra DL, Iloeje UH, Sullivan SD. Cost of chronic hepatitis B infection in the United States. J Clin Gastroenterol. 2004;38(10 suppl 3):S144-S147.
46. Li SC, Ong SC, Lim SG, et al. A cost comparison of management of chronic hepatitis B and its associated complications in Hong Kong and Singapore. J Clin Gastroenterol. 2004;38(10 suppl 3):S136-S143.
47. Yang BM, Kim CH, Kim JY. Cost of chronic hepatitis B infection in South Korea. J Clin Gastroenterol. 2004;38(10 suppl 3):S153-S157.
48. Zhiqiang G, Zhaohui D, Qinhuan W, et al. Cost of chronic hepatitis B infection in China. J Clin Gastroenterol. 2004;38(10 suppl 3):S175-S178.
49. Buti M, Brosa M, Casado MA, Rueda M, Esteban R. Modeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis B. J Hepatol. 2009;51:640-646.
50. Keeffe EB, Dieterich DT, Han SH, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol. 2008;6:1315-1341.
51. Calcagno JI, Augustovski F, Gadano A, Souto A, Yuan Y. Cost-effectiveness analysis of entecavir versus lamivudine in patients with chronic hepatitis B [in Spanish]. Acta Gastroenterol Latinoam. 2008;38:260-273.
52. Kanwal F, Farid M, Martin P, et al. Treatment alternatives for hepatitis B cirrhosis: a cost-effectiveness analysis. Am J Gastroenterol. 2006;101:2076-2089. (Pubitemid 44337634)
53. Lacey LF, Gane E. The cost-effectiveness of long-term antiviral therapy in the management of HBeAg-positive and HBeAg-negative chronic hepatitis B in Singapore. J Viral Hepat. 2007;14:751-766. (Pubitemid 47561579)
54. Spademan DE, Veenstra DL. A cost-effectiveness analysis of currently approved treatments for HBeAg-positive chronic hepatitis B. Pharmacoeconomics. 2008;26:937-949.
55. Sullivan SD, Veenstra DL, Chen PJ, et al. Cost-effectiveness of peginterferon alpha-2a compared to lamivudine treatment in patients with hepatitis B e antigen positive chronic hepatitis B in Taiwan. J Gastroenterol Hepatol. 2007;22:1494-1499. (Pubitemid 47274568)
56. Veenstra DL, Sullivan SD, Lai MY, Lee CM, Tsai CM, Patel KK. HBeAg-negative chronic hepatitis B: cost-effectiveness of peginterferon alfa-2a compared to lamivudine in Taiwan. Value Health. 2008;11:131-138. (Pubitemid 351473598)
57. Yuan Y, Iloeje U, Li H, Hay J, Yao GB. Economic implications of entecavir treatment in suppressing viral replication in chronic hepatitis B (CHB) patients in China from a perspective of the Chinese Social Security program. Value Health. 2008;11(suppl 1):S11-S22. (Pubitemid 351490454)
58. Yuan Y, Iloeje UH, Hay J, Saab S. Evaluation of the cost-effectiveness of entecavir versus lamivudine in hepatitis B e Ag-positive chronic hepatitis B patients. J Manag Care Pharm. 2008;14:21-33. (Pubitemid 351325191)
59. Department of Veterans Affairs Hepatitis C Resource Center; Yee HS, Currie SL, Darling JM, Wright TL. Management and treatment of hepatitis C viral infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center program and the National Hepatitis C Program office. Am J Gastroenterol. 2006;101:2360-2378.
60. Singal AG, Volk ML, Jensen D, Di Bisceglie AM, Schoenfeld PS. A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clin Gastroenterol Hepatol. 2010;8:280-288.
61. Sroczynski G, Esteban E, Conrads-Frank A, et al. Long-term effectiveness and cost-effectiveness of antiviral treatment in hepatitis C. J Viral Hepat. 2010;17:34-50.
62. Campos NG, Salomon JA, Servoss JC et al. Cost-effectiveness of treatment for hepatitis C in an urban cohort co-infected with HIV. Am J Med. 2007;120:272-279. (Pubitemid 46341166)
63. Gerkens S, Nechelput M, Annemans L, Peraux B, Beguin C, Horsmans Y. A health economic model to assess the cost-effectiveness of pegylated interferon alpha-2a and ribavirin in patients with moderate chronic hepatitis C and persistently normal alanine aminotransferase levels. Acta Gastroenterol Belg. 2007;70:177-187. (Pubitemid 47066269)
64. De Compadri P, Koleva D, Mangia A, Motterlini Stat Sci N, Garattini L. Cost minimisation analysis of 12 or 24 weeks of peginterferon alfa-2b + ribavirin for hepatitis C virus. J Med Econ. 2008;11:151-163. (Pubitemid 351613820)
65. Nakamura J, Toyabe SI, Aoyagi Y, Akazawa K. Economic impact of extended treatment with peginterferon alpha-2a and ribavirin for slow hepatitis C virologic responders. J Viral Hepat. 2008;15:293-299. (Pubitemid 351337343)
66. Siebert U, Sroczynski G, Aidelsburger P, et al. Clinical effectiveness and cost effectiveness of tailoring chronic hepatitis C treatment with peginterferon alpha-2b plus ribavirin to HCV genotype and early viral response: a decision analysis based on German guidelines. Pharmacoeconomics. 2009;27:341-354.
67. Tahan V, Ozaras R, Karaca C, et al. Is HCV genotyping cost-effective even when the prevalences of genotypes 2 and 3 are low? Hepatogastroenterology. 2009;56:1425-1428.
68. O'Shea RS, Dasarathy S, McCullough AJ. Alcoholic liver disease. Am J Gastroenterol. 2010;105:14-32.
69. Palmer AJ, Neeser K, Weiss C, Brandt A, Comte S, Fox M. The long-term cost-effectiveness of improving alcohol abstinence with adjuvant acamprosate. Alcohol Alcohol. 2000;35:478-492.
70. Murray KF, Carithers RL Jr. AASLD practice guidelines: evaluation of the patient for liver transplantation. Hepatology. 2005;41:1407-1432. (Pubitemid 40770295)
71. Scarborough JE, Pietrobon R, Marroquin CE, et al. Temporal trends in early clinical outcomes and health care resource utilization for liver transplantation in the United States. J Gastrointest Surg. 2007;11:82-88.
72. Northup PG, Abecassis MM, Englesbe MJ, et al. Adult-to-Adult Living Donor Liver Transplantation Cohort Study Group. Addition of adult-to-adult living donation to liver transplant programs improves survival but at an increased cost. Liver Transpl. 2009;15:148-162.
73. van der Hilst CS, Ijtsma AJ, Slooff MJ, Tenvergert EM. Cost of liver transplantation: a systematic review and meta-analysis comparing the United States with other OECD countries. Med Care Res Rev. 2009;66:3-22.
74. Cholongitas E, Marelli L, Shusang V, et al. A systematic review of the performance of the model for end-stage liver disease (MELD) in the setting of liver transplantation. Liver Transpl. 2006;12:1049-1061. (Pubitemid 44063778)
75. Farnsworth N, Fagan SP, Berger DH, Awad SS. Child-Turcotte-Pugh versus MELD score as a predictor of outcome after elective and emergent surgery in cirrhotic patients. Am J Surg. 2004;188:580-583. (Pubitemid 39491109)
76. Hoteit MA, Ghazale AH, Bain AJ, et al. Model for end-stage liver disease score versus Child score in predicting the outcome of surgical procedures in patients with cirrhosis. World J Gastroenterol. 2008;14:1774-1780. (Pubitemid 351493384)
77. Wiesner R, Edwards E, Freeman R, et al. United Network for Organ Sharing Liver Disease Severity Score Committee. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology. 2003;124:91-96. (Pubitemid 36055342)
78. Axelrod DA, Koffron AJ, Baker T, et al. The economic impact of MELD on liver transplant centers. Am J Transplant. 2005;5:2297-2301. (Pubitemid 41648479)
79. Kogure T, Ueno Y, Kawagishi N, et al. The model for end-stage liver disease score is useful for predicting economic outcomes in adult cases of living donor liver transplantation. J Gastroenterol. 2006;41:1005-1010. (Pubitemid 44741414)
80. Washburn WK, Pollock BH, Nichols L, Speeg KV, Halff G. Impact of recipient MELD score on resource utilization. Am J Transplant. 2006;6:2449-2454. (Pubitemid 44359433)
81. Lopez PM, Martin P. Update on liver transplantation: indications, organ allocation, and long-term care. Mt Sinai J Med. 2006;73:1056-1066. (Pubitemid 46370335)
82. Buchanan P, Dzebisashvili N, Lentine KL, Axelrod DA, Schnitzler MA, Salvalaggio PR. Liver transplantation cost in the model for end-stage liver disease era: looking beyond the transplant admission. Liver Transpl. 2009;15:1270-1277.
83. Ammori JB, Pelletier SJ, Lynch R, et al. Incremental costs of post-liver transplantation complications. J Am Coll Surg. 2008;206:89-95. (Pubitemid 350267243)
84. Saab S, Ham MY, Stone MA, Holt C, Tong M. Decision analysis model for hepatitis B prophylaxis one year after liver transplantation. Liver Transpl. 2009;15:413-420.
85. Gee I, Alexander G. Liver transplantation for hepatitis C virus related liver disease. Postgrad Med J. 2005;81:765-771. (Pubitemid 41826599)
86. Saab S, Ly D, Han SB, et al. Is it cost-effective to treat recurrent hepatitis C infection in orthotopic liver transplantation patients? Liver Transpl. 2002;8:449-457. (Pubitemid 34520774)
87. Russell RT, Feurer ID, Wisawatapnimit P, Lillie ES, Castaldo ET, Pinson CW. Profile of health-related quality of life outcomes after liver transplantation: univariate effects and multivariate models. HPB (Oxford). 2008;10:30-37. (Pubitemid 351298109)
88. Ratcliffe J, Longworth L, Young T, Bryan S, Burroughs A, Buxton M; Cost-Effectiveness of Liver Transplantation Team. Assessing health-related quality of life pre- and post-liver transplantation: a prospective multicenter study. Liver Transpl. 2002;8:263-270. (Pubitemid 34257209)
89. Santos Junior R, Miyazaki MC, Domingos NA, Valério NI, Silva RF, Silva RC. Patients undergoing liver transplantation: psychosocial characteristics, depressive symptoms, and quality of life. Transplant Proc. 2008;40:802-804. (Pubitemid 351608661)
90. Saab S, Wiese C, Ibrahim AB, et al. Employment and quality of life in liver transplant recipients. Liver Transpl. 2007;13:1330-1338. (Pubitemid 47457063)
91. Kousoulas L, Neipp M, Barg-Hock H, et al. Health-related quality of life in adult transplant recipients more than 15 years after orthotopic liver transplantation. Transpl Int. 2008;21:1052-1058.
92. van Ginneken BT, van den Berg-Emons RJ, van der Windt A, et al. Persistent fatigue in liver transplant recipients: a two-year follow-up study. Clin Transplant. 2010;24:E10-E16.
93. Aberg F, Rissanen AM, Simonen H, Roine RP, Höckerstedt K, Isoniemi H. Health-related quality of life and employment status of liver transplant patients. Liver Transpl. 2009;15:64-72.
94. Rongey C, Bambha K, Vanness D, et al. Employment and health insurance in long-term liver transplant recipients. Am J Transplant. 2005;5:1901-1908. (Pubitemid 41039863)
95. Thomas DJ. Returning to work after liver transplant: experiencing the road-blocks. J Transpl Coord. 1996;6:134-138. (Pubitemid 26386140)
96. Castaldo ET, Feurer ID, Russell RT, Pinson CW. Correlation of health-related quality of life after liver transplant with the model for end-stage liver disease score. Arch Surg. 2009;144:167-172.
97. Kanwal F, Gralnek IM, Hays RD, et al. Health-related quality of life predicts mortality in patients with advanced chronic liver disease. Clin Gastroenterol Hepatol. 2009;7:793-799.
98. Kanwal F, Hays RD, Kilbourne AM, Dulai GS, Gralnek IM. Are physician-derived disease severity indices associated with health-related quality of life in patients with end-stage liver disease? Am J Gastroenterol. 2004;99:1726-1732. (Pubitemid 39237500)
99. Saab S, Ibrahim AB, Shpaner A, et al. MELD fails to measure quality of life in liver transplant candidates. Liver Transpl. 2005;11:218-223. (Pubitemid 40268220)
100. Sagmeister M, Wong JB, Mullhaupt B, Renner EL. A pragmatic and cost-effective strategy of a combination therapy of interferon alpha-2b and ribavirin for the treatment of chronic hepatitis C. Eur J Gastroenterol Hepatol. 2001;13:483-488. (Pubitemid 32466248)
101. Stein K, Rosenberg W, Wong J. Cost effectiveness of combination therapy for hepatitis C: a decision analytic model. Gut. 2002;50:253-258. (Pubitemid 34087941)
102. Siebert U, Sroczynski G; German Hepatitis C Model GEHMO Group; HTA Expert Panel on Hepatitis C. Effectiveness and cost-effectiveness of initial combination therapy with interferon/peginterferon plus ribavirin in patients with chronic hepatitis C in Germany: a health technology assessment commissioned by the German Federal Ministry of Health and Social Security. Int J Technol Assess Health Care. 2005;21:55-65. (Pubitemid 40229369)
103. Wong JB, Koff RS. Watchful waiting with periodic liver biopsy versus immediate empirical therapy for histologically mild chronic hepatitis C. A cost-effectiveness analysis. Ann Intern Med. 2000;133:665-675.
104. Sennfält K, Reichard O, Hultkrantz R, Wong JB, Jonsson D. Cost-effectiveness of interferon alfa-2b with and without ribavirin as therapy for chronic hepatitis C in Sweden. Scand J Gastroenterol. 2001;36:870-876. (Pubitemid 32656563)
105. Wong JB, Nevens F. Cost-effectiveness of peginterferon alfa-2b plus ribavirin compared to interferon alfa-2b plus ribavirin as initial treatment of chronic hepatitis C in Belgium. Acta Gastroenterol Belg. 2002;65:110-111. (Pubitemid 34742472)
106. Siebert U, Sroczynski G, Rossol S, et al. Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C. Gut. 2003;52:425-432. (Pubitemid 36250066)
107. Wong JB, Davis GL, McHutchison JG, Manns MP, Albrecht JK; International Hepatitis Interventional Therapy Group. Economic and clinical effects of evaluating rapid viral response to peginterferon alfa-2b plus ribavirin for the initial treatment of chronic hepatitis C. Am J Gastroenterol. 2003;98:2354-2362. (Pubitemid 37448742)
108. Siebert U, Sroczynski G, Wasem J, et al. Using competence network collaboration and decision-analytic modeling to assess the cost-effectiveness of interferon alpha-2b plus ribavirin as initial treatment of chronic hepatitis C in Germany. Eur J Health Econ. 2005;6:112-123. (Pubitemid 40905008)
109. Sroczynski G, Rafetseder O, Jonas S, Siebert U. Antiviral Combination Therapy in Patients with Chronic Hepatitis C in Austria. Health Economic Evaluation of the Antiviral Combination Therapy with Interferon/Peginterferon Plus Ribavirin. ITA project report vol B29. Vienna, Austria: ITA; 2006.
110. Brady B, Siebert U, Sroczynski G, et al. Pegylated Interferon Combined with Ribavirin for Chronic Hepatitis C Virus Infection: An Economic Evaluation. Technology report number 82. Ottawa, Canada: Canadian Agency for Drugs and Technologies in Health; 2007.